Review article · 2024 · Open access

A decade of pyridine-containing heterocycles in US FDA approved drugs: a medicinal chemistry-based analysis

Ashish Ranjan Dwivedi, Shivani Jaiswal, Deepak Kukkar, Roshan Kumar, Thakur Gurjeet Singh, Mahendra Pratap Singh, Abhay Motiramji Gaidhane, Sorabh Lakhanpal, K. Nagendra Prasad, Bhupinder Kumar

RSC Medicinal Chemistry, 16(1), 12–36 · Published 10 October 2024 · DOI 10.1039/d4md00632a

Free PDFView at the publisherCite this paper

In brief

“A decade of pyridine-containing heterocycles in US FDA approved drugs: a medicinal chemistry-based analysis” is a 2024 review article by Ashish Ranjan Dwivedi and 9 co-authors, published in RSC Medicinal Chemistry. OpenAlex counts 124 citations as of 15 November 2026. It is open access: the full text is free to read at PubMed Central.

Citations
124
Most cited in
2026 (76)
Field-weighted impact
3.21
References
107
Authors
10

Abstract

Heterocyclic scaffolds, particularly, pyridine-containing azaheterocycles, constitute a major part of the drugs approved in the past decade. In the present review, we explored the pyridine ring part of US FDA-approved small molecules (2014-2023). The analysis of the approved drugs bearing a pyridine ring revealed that a total of 54 drugs were approved. Among them, the significant number comprised the anticancer category (18 drugs, 33%), followed by drugs affecting the CNS system (11 drugs, 20%), which include drugs to treat migraines, Parkinsonism disorders, chemotherapeutic-induced nausea, insomnia, and ADHD or as CNS-acting analgesics or sedatives. Next, six drugs (11%) were also approved to treat rare conditions, followed by five drugs that affect the hematopoietic system. The analysis also revealed that drug approval was granted for antibiotics, antivirals, and antifungals, including drugs for the treatment of tropical and sub-tropical diseases. Primary drug targets explored were kinases, and the major metabolizing enzyme was CYP3A4. Further analysis of formulation types revealed that 50% of the approved drugs were tablets, followed by 17% capsules and 15% injections. Elemental analysis showed that most approved drugs contained sulfur, while fluorine was noted in 32 compounds. Therefore, the present review is a concerted effort to cover drugs bearing pyridine rings approved in the last decade and provide thorough discussion and commentary on their pharmacokinetics and pharmacodynamics aspects. Furthermore, in-depth structural and elemental analyses were explored, thus providing comprehensive guidance for medicinal chemists and scientists working in allied science domains.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Dwivedi, A. R., Jaiswal, S., Kukkar, D., Kumar, R., Singh, T. G., Singh, M. P., Gaidhane, A. M., Lakhanpal, S., Prasad, K. N., & Kumar, B. (2024). A decade of pyridine-containing heterocycles in US FDA approved drugs: a medicinal chemistry-based analysis. RSC Medicinal Chemistry, 16(1), 12–36. https://doi.org/10.1039/d4md00632a

MLA 9

Dwivedi, Ashish Ranjan, et al. “A decade of pyridine-containing heterocycles in US FDA approved drugs: a medicinal chemistry-based analysis.” RSC Medicinal Chemistry, vol. 16, no. 1, 2024, pp. 12–36. https://doi.org/10.1039/d4md00632a.

Chicago

Dwivedi, Ashish Ranjan, Shivani Jaiswal, Deepak Kukkar, Roshan Kumar, Thakur Gurjeet Singh, Mahendra Pratap Singh, Abhay Motiramji Gaidhane, Sorabh Lakhanpal, K. Nagendra Prasad, and Bhupinder Kumar. 2024. “A decade of pyridine-containing heterocycles in US FDA approved drugs: a medicinal chemistry-based analysis.” RSC Medicinal Chemistry 16 (1): 12–36. https://doi.org/10.1039/d4md00632a.

Harvard

Dwivedi, A. R. et al. (2024) ‘A decade of pyridine-containing heterocycles in US FDA approved drugs: a medicinal chemistry-based analysis’, RSC Medicinal Chemistry, 16(1), pp. 12–36. doi:10.1039/d4md00632a.

IEEE

A. R. Dwivedi et al., “A decade of pyridine-containing heterocycles in US FDA approved drugs: a medicinal chemistry-based analysis,” RSC Medicinal Chemistry, vol. 16, no. 1, pp. 12–36, 2024, doi: 10.1039/d4md00632a.

BibTeX

@article{dwivedi2024decade,
  title     = {{A decade of pyridine-containing heterocycles in US FDA approved drugs: a medicinal chemistry-based analysis}},
  author    = {Dwivedi, Ashish Ranjan and Jaiswal, Shivani and Kukkar, Deepak and Kumar, Roshan and Singh, Thakur Gurjeet and Singh, Mahendra Pratap and Gaidhane, Abhay Motiramji and Lakhanpal, Sorabh and Prasad, K. Nagendra and Kumar, Bhupinder},
  journal   = {RSC Medicinal Chemistry},
  year      = {2024},
  volume    = {16},
  number    = {1},
  pages     = {12--36},
  doi       = {10.1039/d4md00632a},
  url       = {https://doi.org/10.1039/d4md00632a}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202411
20254747
20267676

Its field-weighted citation impact is 3.21: it has been cited 3.21 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods

  • azaheterocycles
  • FDA-approved drugs
  • anticancer agents
  • central nervous system drugs
  • rare disease drugs
  • therapeutic target
  • kinases
  • CYP3A4 metabolism

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Dwivedi, A. R., Jaiswal, S., Kukkar, D., Kumar, R., Singh, T. G., Singh, M. P., Gaidhane, A. M., Lakhanpal, S., Prasad, K. N., & Kumar, B. (2024). A decade of pyridine-containing heterocycles in US FDA approved drugs: a medicinal chemistry-based analysis. RSC Medicinal Chemistry, 16(1), 12–36. https://doi.org/10.1039/d4md00632a

How many times has this paper been cited?

124 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at PubMed Central.

Who wrote this paper?

Ashish Ranjan Dwivedi, Shivani Jaiswal, Deepak Kukkar, Roshan Kumar, Thakur Gurjeet Singh, Mahendra Pratap Singh, Abhay Motiramji Gaidhane, Sorabh Lakhanpal, K. Nagendra Prasad, Bhupinder Kumar.

What is the DOI of this paper?

10.1039/d4md00632a. The permanent link is https://doi.org/10.1039/d4md00632a.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.